Company Description
Lantern Pharma Inc. focuses on the discovery and development of oncology drug.
Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.
In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Panna Sharma |
Contact Details
Address: 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 United States | |
| Phone | 972 277 1136 |
| Website | lanternpharma.com |
Stock Details
| Ticker Symbol | LTRN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001763950 |
| CUSIP Number | 51654W101 |
| ISIN Number | US51654W1018 |
| Employer ID | 46-3973463 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Panna Sharma | President, Chief Executive Officer and Director |
| David R. Margrave | Chief Financial Officer and Secretary |
| Dr. Kishor Gopaldas Bhatia Ph.D. | Chief Scientific Officer and Scientific Consultant |
| Dr. Peter L. Nara D.V.M., M.S., Ph.D. | Co-Founder and Advisor |
| Ernest Kitt B.S., M.S | Head of Clinical Operations |
| Dr. Marc C. Chamberlain M.D. | Chief Medical Officer of Starlight Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | ARS | Filing |
| Aug 8, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 29, 2025 | 8-K | Current Report |
| Jul 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 3, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 424B5 | Filing |
| Jun 13, 2025 | SCHEDULE 13D/A | Filing |
| May 27, 2025 | 144 | Filing |